Expert Interview
A look at the positive results from the Phase 2 Study of NTLA-2002, Intellia's investigational in vivo CRISPR gene editing treatment for HAE
Ticker(s): NTLAInstitution: Penn State University
- Professor, Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine at Penn State University.
- Currently manages over 120 patients with hereditary angioedema and has written guidelines for international management of urticaria, hereditary angioedema and rhinitis with more than 300 publications.
- Clinical research and clinical care focuses include asthma, COPD, alpha-1-antitrypsin deficiency, urticaria, hereditary angioedema, immunodeficiency, vaccine response and other respiratory, allergic and immunologic diseases.
What are the current treatment options available for hereditary angioedema (HAE), and what is considered the standard of care for these patients?
Added By: slingshot_insightsHow effective are the current prophylaxis and on-demand treatments, and what factors influence the choice of treatment for patients?
Added By: slingshot_insightsWhat are the potential benefits and safety concerns associated with Intellia's CRISPR therapy NTLA-2002, and how does it compare to existing and emerging treatments for HAE?
Added By: slingshot_insightsHow do CRISPR gene-editing therapies fit into the current landscape of HAE treatments, and what are the barriers to their widespread adoption in terms of safety, administration, and insurance coverage?
Added By: slingshot_insightsWhich patient profiles would be ideal candidates for NTLA-2002, and what level of long-term safety data would be needed to build confidence in its use?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
